Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis

NCT07571200 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07571200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07571200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
May 14, 2026
Completion date
June 30, 2029
Enrollment
32 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis